
    
      Multicentre phase III, open labelled, randomised controlled trial. Randomisation will be 1:1
      Arm A EOX and Arm B EOX + panitumumab. There will be a pilot phase II study of which the
      first 200 patients will be randomised and the primary endpoint for interim analysis will be
      when these patients have completed 6 months follow-up
    
  